Literature DB >> 16425276

Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors.

Atsushi Inagaki1, Takashi Ishida, Toshihiko Ishii, Hirokazu Komatsu, Shinsuke Iida, Jianmin Ding, Kentaro Yonekura, Shogo Takeuchi, Yoshifusa Takatsuka, Atae Utsunomiya, Ryuzo Ueda.   

Abstract

Patients with adult T-cell leukemia/lymphoma (ATLL) are in a severely immunocompromised state. Therefore, it is assumed that ATLL cells either express particular cytokines or induce their expression in host immune cells, disrupting the balanced production of cytokines and causing the host's immune system to break down. We examined the levels of serum cytokines including T helper type 1- (Th1-) associated cytokines [IFN-gamma, TNF-alpha, and interleukin (IL)-2], Th2-associated cytokines (IL-4, -5 and -6) and regulatory T cell-associated cytokines (IL-10 and TGF-beta1) in 94 ATLL patients, 39 asymptomatic human T-cell lymphotropic virus type-1 (HTLV-1) carriers and 50 healthy adult volunteers, to clarify whether elevated levels of particular cytokines are associated with the prognosis of ATLL patients. On multivariate analysis, high IL-5 and IL-10 levels were independent and significant unfavorable prognostic factors among the ATLL patients. The IL-10 level significantly increased with disease progression at each step from asymptomatic HTLV-1 carrier to ATLL of the indolent variant (chronic and smoldering subtypes) to ATLL of the aggressive variant (acute and lymphoma subtypes). Furthermore, high IL-10 was significantly associated with high lactate dehydrogenase (LDH), indicating that the IL-10 level reflects the tumor burden. The IL-5 level was not associated with disease progression nor LDH. Among ATLL patients with the aggressive variant, high IL-5, but not high IL-10, was an independent and significant unfavorable prognostic factor on multivariate analysis. Measurement of serum IL-5 and IL-10 levels is useful for predicting the prognosis and for determining a suitable treatment strategy for ATLL patients. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16425276     DOI: 10.1002/ijc.21688

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

1.  Quantitative differences in HTLV-I antibody responses: classification and relative risk assessment for asymptomatic carriers and ATL and HAM/TSP patients from Jamaica.

Authors:  Yoshimi Enose-Akahata; Anna Abrams; Kory R Johnson; Elizabeth M Maloney; Steven Jacobson
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

2.  Distinct roles of transforming growth factor-beta-activated kinase 1 (TAK1)-c-Rel and interferon regulatory factor 4 (IRF4) pathways in human T cell lymphotropic virus 1-transformed T helper 17 cells producing interleukin-9.

Authors:  Alaa Refaat; Yue Zhou; Shunsuke Suzuki; Ichiro Takasaki; Keiichi Koizumi; Shoji Yamaoka; Yoshiaki Tabuchi; Ikuo Saiki; Hiroaki Sakurai
Journal:  J Biol Chem       Date:  2011-04-15       Impact factor: 5.157

3.  Evaluation of immunological escape mechanisms in a mouse model of colorectal liver metastases.

Authors:  Martin Grimm; Martin Gasser; Marco Bueter; Johanna Strehl; Johann Wang; Ekaterina Nichiporuk; Detlef Meyer; Christoph T Germer; Ana M Waaga-Gasser; Andreas Thalheimer
Journal:  BMC Cancer       Date:  2010-03-07       Impact factor: 4.430

Review 4.  Colon cancer and the immune system: the role of tumor invading T cells.

Authors:  Maximilian Waldner; Carl-C Schimanski; Markus-F Neurath
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

5.  Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).

Authors:  Takashi Sasayama; Satoshi Nakamizo; Masamitsu Nishihara; Atsufumi Kawamura; Hirotomo Tanaka; Katsu Mizukawa; Shigeru Miyake; Masaaki Taniguchi; Kohkichi Hosoda; Eiji Kohmura
Journal:  Neuro Oncol       Date:  2011-12-12       Impact factor: 12.300

6.  Constitutive release of IFNγ and IL2 from peripheral blood mononuclear cells of rhesus macaques (Macaca mulatta) infected with simian T-lymphotropic virus type 1.

Authors:  JoAnn L Yee; Nestor A Montiel; Amir Ardeshir; Amir Ardeshr; Nicholas W Lerche
Journal:  Comp Med       Date:  2013       Impact factor: 0.982

7.  Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected].

Authors:  Edward L Nelson; Lari B Wenzel; Kathryn Osann; Aysun Dogan-Ates; Nissa Chantana; Astrid Reina-Patton; Amanda K Laust; Kevin P Nishimoto; Alexandra Chicz-DeMet; Nefertiti du Pont; Bradley J Monk
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

8.  Endogenous suppression of mast cell development and survival by IL-4 and IL-10.

Authors:  Kelly Speiran; Daniel P Bailey; Josephine Fernando; Matthew Macey; Brian Barnstein; Motunrayo Kolawole; Dana Curley; Stephanie S Watowich; Peter J Murray; Carole Oskeritzian; John J Ryan
Journal:  J Leukoc Biol       Date:  2009-02-19       Impact factor: 4.962

9.  Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting.

Authors:  Kunihiro Tsukasaki; Olivier Hermine; Ali Bazarbachi; Lee Ratner; Juan Carlos Ramos; William Harrington; Deirdre O'Mahony; John E Janik; Achiléa L Bittencourt; Graham P Taylor; Kazunari Yamaguchi; Atae Utsunomiya; Kensei Tobinai; Toshiki Watanabe
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

10.  Role of interleukin-10 in the regulation of tumorigenicity of a T cell lymphoma.

Authors:  Mona R Hassuneh; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Leuk Lymphoma       Date:  2013-01-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.